The company have substantially advanced the course of a new therapy for cardiac amyloidosis, employing Attruby. Initial clinical information reveals promising improvements for those affected from the severe illness. This effort represents the company’s commitment to managing critical healthcare requirements in this heart space. Attruby:… Read More